Are Peptides Legal in Florida? The 2026 HHS Policy

Not in the formal sense. BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon are not FDA-approved. What changed on October 30, 2026 is narrower: HHS said it does not intend to take enforcement action against state-licensed pharmacies and licensed physicians that compound these six peptides for individual patients, under strict conditions, while the FDA completes rulemaking.

At Padgett Medical Center in Tampa, each of these six peptides is prescribed only after a free consultation with a licensed provider and compounded for the patient by a licensed U.S. compounding pharmacy. Orders start at $90, and new patients who book online with a card on file get 10% off their first peptide order. This guide describes the policy as of November 12, 2026, and the policy may change.

What did HHS announce in October 2026?

On October 28, 2026, the U.S. Department of Health and Human Services announced an enforcement discretion policy for compounding certain peptides, and the Federal Register published its notice on October 30, 2026 (FR Doc. 2026-22192). The Office of the Secretary issued it, not the FDA. It says that while the FDA builds, through formal rulemaking, the list of bulk substances pharmacies may compound from, HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound six peptides: BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon.

Enforcement discretion means the government is choosing not to act against something it could act against. It is not an approval, it creates no rights, and it is not binding on HHS or the public. HHS gave two reasons for it: there are no approved products for these peptides, and it wants to discourage the continued, widespread use of peptides labeled "research use only" by offering "a more controlled alternative".

Is the HHS peptide policy final?

Not necessarily. The Federal Register notice announces the availability of a draft policy, with comments open for two weeks, to about November 13, 2026. Some legal commentators treat it as an operating interim policy now, and others call it a draft. HHS may revise it after comments close. It lasts until the FDA decides each peptide in a final rule, and HHS says it may revisit the policy in whole or in part if a safety signal or a product quality problem comes up.

Which peptides and forms does the policy cover?

Six peptides, each only in the forms the policy lists. BPC-157: injection under the skin or into a muscle, by mouth, or on the skin. TB-500: injection under the skin or into a muscle. Epitalon: injection under the skin or into a muscle, in intermittent courses. MOTS-c: injection under the skin or into a muscle. Semax: a nasal spray. KPV: by mouth or on the skin.

A form that is not on the list falls outside the policy, even for a listed peptide. Padgett offers each peptide only in a listed form: BPC-157 as capsules or an injection, TB-500 as an injection, KPV as capsules, MOTS-c as an injection, Semax as a nasal spray and Epitalon as an injection. Every product and price is published.

What conditions do pharmacies have to meet?

Every condition has to be met for the policy to apply. They include a prescription for each individual patient; a bulk ingredient from an FDA-registered facility, with a certificate of analysis covering identity, purity, potency and contaminants such as endotoxins, heavy metals and microbes; an original manufacturer that is FDA-registered and follows current good manufacturing practice; reporting serious side effects and quality problems to FDA MedWatch and the states; a label that reads "This is a compounded drug product. Not for resale."; for any form taken by mouth, documentation that enough of the peptide is absorbed in people; an FDA-cleared syringe as the only device packed with it; and only one of the six peptides in each product.

That last condition means blends are not covered. A vial that combines BPC-157 and TB-500, for example, falls outside the policy, so if a provider prescribes two peptides, each has to be its own product. Every other federal requirement still applies too, including the ban on insanitary conditions, and so does state law. BPC-157 vs TB-500 explains how the two are prescribed separately.

Does this mean peptides are FDA-approved?

No. Compounded peptides have not been approved by the FDA. The notice itself states that compounded drugs are not FDA-approved. The policy does not put these peptides on the FDA's list of substances pharmacies may compound from, and it does not show that they are safe or effective. A seller who calls one of these peptides "FDA approved" is not telling you the truth.

Why were these peptides restricted before?

In 2023, the FDA placed the bulk substances for these peptides in Category 2 of its interim compounding policy, its list of substances that may present significant safety risks, which in practice meant pharmacies could not compound them. The FDA listed concerns including possible immune reactions, peptide-related impurities and limited or no human safety data, and found no human exposure data at all for TB-500, KPV or MOTS-c. On April 22, 2026, the FDA took them out of Category 2 because the nominations were withdrawn, which on its own did not make them eligible for compounding.

In July 2026, the FDA's Pharmacy Compounding Advisory Committee reviewed them. FDA staff recommended against adding any of them to the list, and the committee voted, narrowly, to recommend six: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. That vote was advisory. The October HHS policy set aside the staff recommendation and relied instead on the committee vote, additional data from FDA-registered sources, historical use and the policy's safeguards.

Does the policy cover research peptides sold online?

No. It does not cover products sold as research chemicals or dietary supplements. The FDA sent warning letters to online sellers of "research use only" peptides in 2026, saying evidence on their websites showed the products were "intended to be drugs for human use" and calling them unapproved new drugs.

At Padgett Medical Center in Tampa, peptides are prescribed only after a consultation with a licensed medical provider, and each one is compounded for the individual patient by a licensed U.S. compounding pharmacy. That is not the same as the "research grade" or "research use only" peptides sold online, which are labeled not for human use and are not made or checked to pharmacy standards for people, so there is no way to be sure of their strength, purity or sterility, or how well they will work. Research-grade vs pharmacy-compounded peptides covers the FDA letters and testing in detail.

Does the policy apply in Florida?

Yes. It is a federal policy, so it covers state-licensed pharmacies and licensed physicians in Florida as it does elsewhere. It does not replace Florida's own rules: the policy does not bind state boards, and Florida pharmacy and medical rules still apply alongside it.

Do you need a prescription for peptides in Florida?

For a compounded peptide, yes. The policy keeps the federal requirement of a prescription for each individual patient. At Padgett, every peptide is prescribed by a licensed provider after a free consultation, in person at our Tampa clinic or by telehealth from anywhere in Florida. Book a free consultation and pick the peptides you want to ask about, such as BPC-157 or Semax.

What could change?

Several things could. HHS may revise the draft after comments close, the FDA still has to decide each peptide through a final rule, and HHS may revisit the policy if safety or quality problems come up. The last comparable rulemaking took more than two years, from a proposed rule in December 2016 to a final rule in February 2019. If the policy changes, what pharmacies may compound, and what Padgett can offer, may change with it.

This article is educational and is not medical advice. Talk with a licensed provider about your own health, medications and treatment options.